01:18:01 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-04-03 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-01 Ordinarie utdelning NSIS B 2.00 DKK
2024-04-30 Årsstämma 2024
2024-03-04 Extra Bolagsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-10-13 Bonusutdelning NSIS B 4.2
2023-08-09 Kvartalsrapport 2023-Q2
2023-04-26 Kvartalsrapport 2023-Q1
2023-03-30 Extra Bolagsstämma 2023
2023-03-03 Ordinarie utdelning NSIS B 6.00 DKK
2023-03-02 Årsstämma 2023
2023-01-26 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-04-27 Kvartalsrapport 2022-Q1
2022-03-17 Ordinarie utdelning NSIS B 5.50 DKK
2022-03-16 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-27 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-12 Ordinarie utdelning NSIS B 5.25 DKK
2021-03-11 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Ordinarie utdelning NSIS B 5.25 DKK
2020-02-26 Årsstämma 2020
2020-01-23 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-28 Ordinarie utdelning NSIS B 5.00 DKK
2019-02-27 Årsstämma 2019
2019-01-24 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-14 Ordinarie utdelning NSIS B 4.50 DKK
2018-03-13 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-11 Kvartalsrapport 2017-Q2
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-23 Ordinarie utdelning NSIS B 4.00 DKK
2017-02-22 Årsstämma 2017
2017-01-18 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-04-20 Kvartalsrapport 2016-Q1
2016-02-25 Ordinarie utdelning NSIS B 3.50 DKK
2016-02-24 Årsstämma 2016
2016-01-19 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-02-26 Ordinarie utdelning NSIS B 3.00 DKK
2015-02-25 Årsstämma 2015
2015-01-20 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-02-27 Ordinarie utdelning NSIS B 2.50 DKK
2014-02-26 Årsstämma 2014
2014-01-21 Bokslutskommuniké 2013
2013-10-25 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-01 Ordinarie utdelning NSIS B 2.20 DKK
2013-02-28 Årsstämma 2013
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-25 Kvartalsrapport 2012-Q1
2012-03-01 Ordinarie utdelning NSIS B 1.90 DKK
2012-02-29 Årsstämma 2012
2012-01-19 Bokslutskommuniké 2011
2011-11-28 Split NSIS B 1:5
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-11 Kvartalsrapport 2011-Q2
2011-04-29 Kvartalsrapport 2011-Q1
2011-03-03 Ordinarie utdelning NSIS B 8.00 DKK
2011-03-02 Årsstämma 2011
2011-01-21 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-12 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-03-04 Ordinarie utdelning NSIS B 5.75 DKK
2010-03-03 Årsstämma 2010
2009-03-05 Ordinarie utdelning NSIS B 5.25 DKK
2008-03-06 Ordinarie utdelning NSIS B 5.00 DKK
2007-03-09 Ordinarie utdelning NSIS B 4.50 DKK
2006-03-02 Ordinarie utdelning NSIS B 4.00 DKK
2005-03-17 Ordinarie utdelning NSIS B 3.50 DKK
2004-03-18 Ordinarie utdelning NSIS B 3.15 DKK
2003-03-20 Ordinarie utdelning NSIS B 2.25 DKK
2002-03-21 Ordinarie utdelning NSIS B 2.00 DKK
2001-03-22 Ordinarie utdelning NSIS B 1.65 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Novonesis är verksamma inom biokemi. Bolaget utvecklar enzymer och mikroorganismer för industriellt bruk. Enzymerna är ett protein som används inom ett flertal olika branscher, huvudsakligen inom jordbruks- och livsmedelsindustrin. Produkterna används inom livsmedel samt kläder, och försäljning innehas på global nivå, med störst närvaro inom Norden och Europa. Bolaget har sitt huvudkontor i Bagsværd.
2023-09-28 08:48:27

Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices.

Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the launch of Vertera® ProBite, a solution set to advance the plant-based meat industry by changing the need for manufacturers’ use of unwanted texturizers to a natural alternative. Developed by global biosolutions provider, Novozymes, Vertera® ProBite will address and resolve the primary consumer concerns of texture and long ingredient lists and encourage more individuals to make the switch from traditional meat to plant-based alternatives.

"This product launch represents a significant milestone in the plant-based meat sector. Vertera® ProBite has the potential to redefine the consumer experience by improving the texture issue and at the same time enable a more consumer-friendly label. Two areas which are still hindering the widespread adoption of plant-based alternatives," said Birgitte Schou Borch, Head of the Plant & Food Business, Novozymes. 

Vertera® ProBite is an innovation based on the enzyme MTGase (microbial transglutaminase E.C. 2.3.2.13), designed to enhance the texture of plant-based products. Unlike previous solutions, Vertera® ProBite offers the unique advantage of requiring no labeling, marking a significant breakthrough for the plant-based meat industry.

The key features of Vertera® ProBite include:

  • Texture Enhancement: Vertera® ProBite has been specifically engineered to address the texture issue in plant-based meat products. It delivers an exceptional mouthfeel and consistency, ensuring a more satisfying culinary experience for consumers.
  • Simple label: Vertera® ProBite is approved as a processing aid, with its technological function fully realized during the food processing stage. This innovative approach means that any unintentional but technically unavoidable presence of the enzyme in the final product does not necessitate labeling, which will eliminate potential barriers to market entry by offering transparency and simplicity to consumers and enable to elimination of unwanted texturizers.
  • Ease of Handling: Vertera® ProBite is a liquid product, making it incredibly easy to dose and handle safely during food production. Its user-friendly nature is a boon for food manufacturers seeking efficiency in their operations.

Novozymes is committed to driving innovation in biosolutions and promoting sustainable food choices. Vertera® ProBite is another testament to the company's dedication to making the transition to plant-based diets more accessible and enjoyable for consumers worldwide.

About Novozymes
Novozymes is the world leader in biological solutions. Together with customers, partners, and the global community, we improve industrial performance while preserving the planet's resources and helping build better lives. As the world's largest provider of enzyme and microbial technologies, our bioinnovation enables higher agricultural yields, low-temperature washing, energy-efficient production, renewable fuel, and many other benefits that we rely on today and in the future. We call it Rethink Tomorrow. Read more about Vertera® Probite here.
 
 NASDAQ OMX: NZYM-B • 6,500 employees • DKK 15 billion turnover • 30+ industries • 700+ products

Media Relations  
Lina Danstrup
Head of External Communications
Phone: +45 30 77 05 52
lind@novozymes.com

 
 
   
Investor Relations  
Tobias Cornelius Björklund
Head of Investor Relations
Phone: +45 30 77 86 82
tobb@novozymes.com